TrueNorth Inc. decreased its position in shares of Cambrex Co. (NYSE:CBM) by 43.9% in the fourth quarter, HoldingsChannel reports. The firm owned 36,635 shares of the biotechnology company’s stock after selling 28,709 shares during the quarter. TrueNorth Inc.’s holdings in Cambrex were worth $1,758,000 at the end of the most recent reporting period.
Several other institutional investors have also recently modified their holdings of the company. Boston Partners lifted its holdings in shares of Cambrex by 118.5% in the 4th quarter. Boston Partners now owns 709,786 shares of the biotechnology company’s stock valued at $34,069,000 after acquiring an additional 384,897 shares during the last quarter. Peregrine Capital Management LLC bought a new position in shares of Cambrex in the 4th quarter valued at about $9,780,000. FMR LLC lifted its holdings in shares of Cambrex by 19.1% in the 2nd quarter. FMR LLC now owns 1,070,645 shares of the biotechnology company’s stock valued at $63,971,000 after acquiring an additional 171,559 shares during the last quarter. Brown Advisory Inc. lifted its holdings in shares of Cambrex by 1,638.7% in the 3rd quarter. Brown Advisory Inc. now owns 161,577 shares of the biotechnology company’s stock valued at $8,888,000 after acquiring an additional 152,284 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Cambrex by 117.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 231,931 shares of the biotechnology company’s stock valued at $12,721,000 after acquiring an additional 125,062 shares during the last quarter.
Shares of Cambrex Co. (NYSE CBM) opened at $52.30 on Tuesday. The stock has a market cap of $1,789.66, a PE ratio of 17.43, a price-to-earnings-growth ratio of 1.30 and a beta of 2.38. Cambrex Co. has a 12 month low of $42.55 and a 12 month high of $62.95.
CBM has been the subject of a number of analyst reports. Zacks Investment Research raised shares of Cambrex from a “strong sell” rating to a “hold” rating in a report on Monday, January 15th. Craig Hallum reaffirmed a “buy” rating and issued a $60.00 price target (down previously from $70.00) on shares of Cambrex in a report on Tuesday, October 31st. Finally, William Blair initiated coverage on shares of Cambrex in a report on Tuesday, January 16th. They issued an “outperform” rating for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $60.50.
TRADEMARK VIOLATION NOTICE: This report was posted by Stock Observer and is owned by of Stock Observer. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.thestockobserver.com/2018/02/06/cambrex-co-cbm-shares-sold-by-truenorth-inc.html.
Cambrex Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.